

Greater Manchester Medicines Management Group

Minutes of the meeting held on
Thursday 14th October 2021, 1- 3pm

Virtual meeting

Present:

Name	Title	Organisation	Representing	Sept	Oct	Nov 20	May 21	Jun	Aug	Oct
Dr Helen Burgess (HB)	GP MO Prescribing lead	NHS Manchester CCGs	GPs	✓	✓	✓	✓	✓	✓	A
Petra Brown (PeB)	Chief Pharmacist	Pennine care NHS FT	GM Mental Health Organisations	✓ (JW)	✓	✓	✓	✓	✓	✓
Kate Rigden (KR)	Chief Finance Officer	NHS Oldham CCG	CCG finance leads	✓	✓	✓	✓	A	AF	✓
Ruth Dales (RuD)	Lead Pharmacist	GM AHSN	Health Innovation Manchester (HIM)	✓	✓	✓	A	✓	A	
Dr Ann Harrison (AH)	GP MO Prescribing lead	Trafford CCG	GPs	✓	✓	✓	✓	✓	✓	✓
Robert Hallworth (RH)	Specialist Cancer Pharmacist	NHSE	NHSE Specialised Commissioning	A	✓	✓	✓	✓	✓	✓
Peter Howarth (PH)	Head of Medicines Management	Tameside & Glossop CCG	CCG MO leads	✓	✓	✓	✓	✓	✓	✓
Aneet Kapoor	Chair of the GM LPN	LPN	Pharmacy profession						✓	✓

Dr Daljit Saroya	Consultant Anaesthetist and Chair of MO committee at Stockport FT	Stockport FT	GM Secondary Care Clinicians	✓	✓						
Leigh Lord (LL)	Locality Lead Pharmacist	NHS Trafford CCG	CCG MO leads	✓	✓	✓	✓		✓	✓	✓
Peter Marks (PM)	LPC Board Member	GM LPC	Community Pharmacy	✓	✓	✓	A	✓	✓	✓	
Luvjit Kandula (LK)	Chair – Community Pharmacy Provider Board (CPPB)	GM LPC	Community Pharmacy				✓		✓		
Fiona Meadowcroft (FC)	Interim Deputy Director Strategy – Integrated Care	MHCC	CCG Commissioning lead	✓	✓	✓	✓	✓	✓	✓	✓
Karen O’Brien (KO’B)	Regional Pharmacist	NHSEI	NHSEI	✓	✓	✓	✓	✓	✓	✓	✓
Rob Bellingham	Managing Director Greater Manchester Joint Commissioning Team	The GM Joint Commissioning Board (MO)	Joint Commissioning Board								✓
Paul Buckley (PaB)	Chief Pharmacist	Stockport FT	GM Chief pharmacists	✓			✓	✓	✓		A
Steve Simpson (SS)	Chief Pharmacist	Bolton FT	GM Chief pharmacists	A	✓	✓	✓	✓		A	✓
Charlotte Skitterall (CS)	Chief Pharmacist	Manchester FT	Chair	A	✓	✓	✓	✓	✓	✓	✓
Claire Vaughan (CV)	Head of MO	Salford CCG	Vice Chair	✓	✓	✓	✓	✓		A	✓
Dr Sanjay Wahie (SW)	Clinical Director	NHS Wigan CCG	GPs	✓	✓	A	✓	✓		A	✓
Dr Peter Elton	SCN representatives	Strategic Clinical Network	Strategic Clinical Network	✓	✓	✓	✓	✓	✓		A

Vacant seat			Provider Board representative							
Vacant seat			Council representative for GM Social Services							
Vacant seat			GM Medical Directors							
Vacant seat			Lay representative							
Vacant seat			GM Public Health							
Sue Dickinson (SD)	Director of Pharmacy	RDTC	SPS	✓	✓	✓	✓	✓	A	✓
Monica Mason (MM)	Head of Prescribing Support	RDTC	Professional secretary	✓	✓	✓	✓	✓	✓	✓
Andrew Martin (AM)	MO Pharmacist	GM Joint Commissioning team	GMMMGM support	✓ AM	✓	✓	✓	✓	✓	✓
Andrew White (AW)	Head of MO	GM Joint Commissioning team	GMMMGM support	✓	✓	✓	✓	✓	✓	✓
Dan Newsome (DN)	Principal pharmacist	RDTC	GMMMGM support	✓	✓	✓				✓

1. General Business

1.1 Apologies

As above. It was noted that the HiM seat is now open, but Dai Roberts attended from HiM to support the discussions on inclisiran

1.2 Declarations of Interest

Nil declared

2.0 Minutes and actions from the last meeting

The minutes of the August meeting (no September meeting) were approved for publication; the group were updated on the progress of outstanding actions as recorded in the action log

3.0 Revised Primary Care Rebate Scheme (PCRS) Ethical Framework

The revised PCRS ethical framework was presented to GMMMGM as discussed at the August meeting and approved. The possible impact on community pharmacy was acknowledged, and the importance of clear, timely communication between the individual CCG and their community pharmacies was emphasised. It was accepted that the financial benefits to the system needed to be realised, and that primary care rebates would be communicated as part of the primary care financial savings plan to the Primary Care Cell.

The following rebate recommendations were accepted by the group:

- Dalonev ointment (Category A) – recommended for approval
- Freestyle Libre – recommended to be rejected
- Pipexus (Category A) recommended for approval

The group delegated the approval of rebate recommendations to MGSG, but confirmed that any changes to the framework must be brought to GMMMGM for approval.

It was recommended by GMMMGM that if a CCG is not participating in any one of the approved rebate schemes they should make their CCG finance officer aware.

It was agreed that AM would produce an FAQ document to address common queries associated with PCRS.

Action: AM to make the final minor amendments to the PCRS framework which will be approved by GMMMGM Chairs. AM to draft a FAQ guide and seek GMMMGM approval. LL/PH to take a paper detailing the financial benefits of rebate schemes to the primary care cell.

4.0 GMMMGM subgroup decisions for ratification (August, September)

Recommendations and decisions made by CRG and MGSG in August and September were ratified. It was noted that decisions are pending ongoing service implication discussions for Sativex® for spasticity in adults with MS, and andexanet alfa (TA697). It was agreed that the RAG status for demeclocycline be annotated to reflect use in “new” patients.

It was noted that the HCD assurance framework paper recommended for submission to GMMMGM by MGSG had not been accepted onto the GMMMGM agenda yet, GMMMGM Chairs offered to support the further development of this paper, so it could be considered by GMMMGM.

Action: RDTC to publish the approved decisions via the GMMMGM website. CS and CV to meet with authors of the HCD assurance paper (SJ) to support its development prior to its submission to GMMMGM

5.0 Implementation of national direction on Inclisiran across GM

The group were provided an overview of the direction from NHSEI to make available inclisiran (NICE TA 733). The group expressed their concern as to the unusual and rapid nature of this direction, which would see this agent listed as a green drug in the formulary within 30 days of the TA publishing. The group accepted the direction but asked that MGSG who were meeting the following week, discuss further what practical support was being made available to primary care teams to support implementation. It was agreed that Health Innovation Manchester would attend MGSG to provide information on the development of implementation support packs.

Action: MGSG to discuss in further detail with HiM with regards the implementation support available. This item is to return to GMMMGM in November for approval of the RAG/formulary position.

6.0 Good for you, good for us, good for everybody

The group noted the September 2021 publication of “Good for you, good for us, good for everybody”: A plan to reduce overprescribing to make patient care better and safer, support the NHS, and reduce carbon emissions”. It was noted that subgroup discussions are already underway as to how to take forward implementation of this guidance and it will be discussed further at GMMMGM in due course.

Action: Subgroup to return plan to future GMMMGM

7.0 Neutralising Monoclonal Antibodies (nMABs): GM update

Tim Felton attended to update GMMMGM on the use of NMABs, the possible routes of delivery were discussed and it was agreed that there was a need to work as a system, and that GMMMGM could support the development of pathways and SOPs through a short life working group, which should be representative of all GM sectors.

Action: GMMMG colleagues to express their interest in the SLWG to CS

8.0 Communication from Subgroups and Associated Committees

Due to insufficient time members were asked to share anything significant with the group by email.

Date of next virtual meeting: Thursday 11th Nov 2021, 1 – 3pm